Gut check: could your microbiome boost lymphoma therapy?

NCT ID NCT07498920

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the bacteria living in your gut can influence how well a drug called glofitamab works against diffuse large B-cell lymphoma (DLBCL). Researchers will collect stool samples from 30 patients before and after treatment to track changes in gut microbiome and see if they relate to treatment response or side effects. The goal is to understand if the gut microbiome can be used to improve outcomes for lymphoma patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could reveal how gut bacteria influence the effectiveness of glofitamab in lymphoma patients, potentially guiding future personalized treatments.

What could go wrong

This is a small, early observational study (30 people) that does not test a new treatment. It may not find a clear link between gut microbiome and therapy outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••